Sanofi SA said that the first of two randomised Phase 3 clinical trials of its antibody, alemtuzumab, showed a statistically significant improvement in patients with relapsing-remitting multiple sclerosis compared with interferon beta-1a. ---Subscribe to MedNous to access this article--- Research & University News Company News
